Appetite suppressant approved by NICE for patients with obesity
The National Institute for Health and Care Excellence recommends that semaglutide should be considered in adults with at least one weight-related condition and a body mass index of at least 35.
Semaglutide, which is self-injected using weekly pre-filled pens, acts as an appetite suppressant by mimicking the hormone glucagon-like peptide-1 released naturally after eating
Shutterstock.com
The National Institute for Health and Care Excellence (NICE) has confirmed draft guidance recommending the use of semaglutide, an appetite suppressant, for overweight and obese adults in the UK.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
